Comment by bjoernw

Is it worth optimizing for future output when the life-saving metric during a global pandemic is time-to-first-dose? There are only a few factories in the world that can make something as complex as an mRNA vaccine. There is literally a shortage in glass beakers and shipping lanes are backlogged. These supply chains are very fragile and helping stabilize those would do more for vaccine supply than what's being proposed here.